2020 ESMO IPATential150 Trial Data on mCRPC: Does Ipatasertib Combined With Abiraterone Acetate + Prednisone Lead to a Significantly Superior rPFS and Antitumor Activity in PTEN Loss Disease?
By
Dana-Farber Cancer Institute
FEATURING
Christopher Sweeney
By
Dana-Farber Cancer Institute
FEATURING
Christopher Sweeney
Login to view comments.
Click here to Login